Literature DB >> 33352100

COVID-19 Treatment at a Glance.

Hüseyin Arıkan1, Dilek Karadoğan2, Fatma Tokgöz Akyıl3, Aycan Yüksel4, Zehra Nur Töreyin5, Canan Gündüz Gürkan6, Feride Marim7, Tuğba Şişmanlar Eyüboğlu8, Nagehan Emiralioğlu9, Tuğba Ramaslı Gürsoy8, İrem Şerifoğlu10, Abdulsamet Sandal11, Aslı Öncel12, Berrin Er13, Neslihan Köse14, Dorina Esendağlı15, Mina Hızal16, Aslıhan Banu Er17, Fatma Esra Günaydın18, İlknur Kaya19, Hilal Özakıncı20, Ümran Özden Sertçelik12, Hatice Çelik Tuğlu21, Nilüfer Aylin Acet Özürk18, Özlem Ataoğlu22, Ahu Cerit Çakır23, Hüseyin Toptay24, Merve Erçelik22, Elif Develi25, Selman Çelik26, Fatma Gülsüm Karakaş27, Halime Yıldırım28, Damla Karadeniz Güven12, Nazlı Çetin29, Sümeyye Nur Aslan Küçükyurt30, Mehmet Fatih Elverişli31, Pinar Yıldız Gülhan32, Metin Akgün33.   

Abstract

As coronavirus disease 2019 (COVID-19) spreads across the world, the ongoing clinical trials are leading to a big race worldwide to develop a treatment that will help control the pandemic. Unfortunately, COVID-19 does not have any known effective treatment with reliable study results yet. In this pandemic, there is not a lot of time to develop a new specific agent because of the rapid spread of the disease. The process of developing a vaccine is long and requires hard work. Although the pathophysiology of the disease is not fully understood, some of the proposed treatment alternatives are based on old evidence and some have been used with the idea that they might work owing to their mechanism of action. The efficacy, reliability, and safety of the currently available treatment alternatives are therefore a matter of debate. Currently, the main therapies used in the treatment of COVID-19 are antiviral drugs and chloroquine/hydroxychloroquine. Other proposed options include tocilizumab, convalescent plasma, and steroids, but the mainstay of the treatment in intensive care units remains supportive therapies.

Entities:  

Year:  2020        PMID: 33352100      PMCID: PMC7752114          DOI: 10.5152/TurkThoracJ.2020.20125

Source DB:  PubMed          Journal:  Turk Thorac J        ISSN: 2148-7197


  63 in total

1.  Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?

Authors:  Daniel Batlle; Jan Wysocki; Karla Satchell
Journal:  Clin Sci (Lond)       Date:  2020-03-13       Impact factor: 6.124

2.  A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.

Authors:  Sabue Mulangu; Lori E Dodd; Richard T Davey; Olivier Tshiani Mbaya; Michael Proschan; Daniel Mukadi; Mariano Lusakibanza Manzo; Didier Nzolo; Antoine Tshomba Oloma; Augustin Ibanda; Rosine Ali; Sinaré Coulibaly; Adam C Levine; Rebecca Grais; Janet Diaz; H Clifford Lane; Jean-Jacques Muyembe-Tamfum; Billy Sivahera; Modet Camara; Richard Kojan; Robert Walker; Bonnie Dighero-Kemp; Huyen Cao; Philippe Mukumbayi; Placide Mbala-Kingebeni; Steve Ahuka; Sarah Albert; Tyler Bonnett; Ian Crozier; Michael Duvenhage; Calvin Proffitt; Marc Teitelbaum; Thomas Moench; Jamila Aboulhab; Kevin Barrett; Kelly Cahill; Katherine Cone; Risa Eckes; Lisa Hensley; Betsey Herpin; Elizabeth Higgs; Julie Ledgerwood; Jerome Pierson; Mary Smolskis; Ydrissa Sow; John Tierney; Sumathi Sivapalasingam; Wendy Holman; Nikki Gettinger; David Vallée; Jacqueline Nordwall
Journal:  N Engl J Med       Date:  2019-11-27       Impact factor: 91.245

Review 3.  Hemophagocytic Lymphohistiocytosis.

Authors:  Hanny Al-Samkari; Nancy Berliner
Journal:  Annu Rev Pathol       Date:  2017-09-13       Impact factor: 23.472

4.  Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.

Authors:  Bruno M Tomazini; Israel S Maia; Alexandre B Cavalcanti; Otavio Berwanger; Regis G Rosa; Viviane C Veiga; Alvaro Avezum; Renato D Lopes; Flavia R Bueno; Maria Vitoria A O Silva; Franca P Baldassare; Eduardo L V Costa; Ricardo A B Moura; Michele O Honorato; Andre N Costa; Lucas P Damiani; Thiago Lisboa; Letícia Kawano-Dourado; Fernando G Zampieri; Guilherme B Olivato; Cassia Righy; Cristina P Amendola; Roberta M L Roepke; Daniela H M Freitas; Daniel N Forte; Flávio G R Freitas; Caio C F Fernandes; Livia M G Melro; Gedealvares F S Junior; Douglas Costa Morais; Stevin Zung; Flávia R Machado; Luciano C P Azevedo
Journal:  JAMA       Date:  2020-10-06       Impact factor: 56.272

5.  Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.

Authors:  Eli S Rosenberg; Elizabeth M Dufort; Tomoko Udo; Larissa A Wilberschied; Jessica Kumar; James Tesoriero; Patti Weinberg; James Kirkwood; Alison Muse; Jack DeHovitz; Debra S Blog; Brad Hutton; David R Holtgrave; Howard A Zucker
Journal:  JAMA       Date:  2020-06-23       Impact factor: 56.272

6.  First Case of 2019 Novel Coronavirus in the United States.

Authors:  Michelle L Holshue; Chas DeBolt; Scott Lindquist; Kathy H Lofy; John Wiesman; Hollianne Bruce; Christopher Spitters; Keith Ericson; Sara Wilkerson; Ahmet Tural; George Diaz; Amanda Cohn; LeAnne Fox; Anita Patel; Susan I Gerber; Lindsay Kim; Suxiang Tong; Xiaoyan Lu; Steve Lindstrom; Mark A Pallansch; William C Weldon; Holly M Biggs; Timothy M Uyeki; Satish K Pillai
Journal:  N Engl J Med       Date:  2020-01-31       Impact factor: 91.245

Review 7.  Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.

Authors:  Imad M Tleyjeh; Zakariya Kashour; Moussab Damlaj; Muhammad Riaz; Haytham Tlayjeh; Mustafa Altannir; Youssef Altannir; Mohamad Al-Tannir; Rana Tleyjeh; Leslie Hassett; Tarek Kashour
Journal:  Clin Microbiol Infect       Date:  2020-11-05       Impact factor: 8.067

8.  Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.

Authors:  Shruti Gupta; Wei Wang; Salim S Hayek; Lili Chan; Kusum S Mathews; Michal L Melamed; Samantha K Brenner; Amanda Leonberg-Yoo; Edward J Schenck; Jared Radbel; Jochen Reiser; Anip Bansal; Anand Srivastava; Yan Zhou; Diana Finkel; Adam Green; Mary Mallappallil; Anthony J Faugno; Jingjing Zhang; Juan Carlos Q Velez; Shahzad Shaefi; Chirag R Parikh; David M Charytan; Ambarish M Athavale; Allon N Friedman; Roberta E Redfern; Samuel A P Short; Simon Correa; Kapil K Pokharel; Andrew J Admon; John P Donnelly; Hayley B Gershengorn; David J Douin; Matthew W Semler; Miguel A Hernán; David E Leaf
Journal:  JAMA Intern Med       Date:  2021-01-01       Impact factor: 21.873

9.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245

10.  Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.

Authors:  Giorgio Bozzi; Davide Mangioni; Francesca Minoia; Stefano Aliberti; Giacomo Grasselli; Laura Barbetta; Valeria Castelli; Emanuele Palomba; Laura Alagna; Andrea Lombardi; Riccardo Ungaro; Carlo Agostoni; Marina Baldini; Francesco Blasi; Matteo Cesari; Giorgio Costantino; Anna Ludovica Fracanzani; Nicola Montano; Valter Monzani; Antonio Pesenti; Flora Peyvandi; Marcello Sottocorno; Antonio Muscatello; Giovanni Filocamo; Andrea Gori; Alessandra Bandera
Journal:  J Allergy Clin Immunol       Date:  2020-11-19       Impact factor: 10.793

View more
  2 in total

1.  Efficacy of High-Dose Nebulized Interferon α 2b in Severe COVID-19 Pneumonia.

Authors:  Ayman Chkhis; Najiba Abdulrazzaq; Sherif Mokhtar; Alia Al Jasmi
Journal:  Turk Thorac J       Date:  2021-05

2.  Immune modulation as a consequence of SARS-CoV-2 infection.

Authors:  Metin Yusuf Gelmez; Fatma Betul Oktelik; Ilhan Tahrali; Vuslat Yilmaz; Umut Can Kucuksezer; Nilgun Akdeniz; Esin Aktas Cetin; Murat Kose; Cigdem Cinar; Fatma Savran Oguz; Sevgi Besisik; Kaya Koksalan; Ozkan Ozdemir; Naci Senkal; Ahmet Gul; Erdem Tuzun; Gunnur Deniz
Journal:  Front Immunol       Date:  2022-08-30       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.